1Q22 Business Results

Key Business Performance TruximaⓇ ✓ Sales and market share decreased temporally due to the preparation for the additional direct sales as well as strategically participating in tenders to secure profitability in Europe ✓ Optimal pricing strategy in the US contributed to securing profitability as well as steady rise in the market share Market share of TruximaⓇ in Europe 2% 18% 31% 38% 39% 40% 36% 37% 36% Market share of TruximaⓇ in the US Volume 34% 27% 19.4Q 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q TruximaⓇ D Biosimilar Value 29% 29% 27% 17.2Q 4Q 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 21.2Q 4Q 19.4Q 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 22.1Q MabtheraⓇ Truxima a® C Biosimilar TruximaⓇ D Biosimilar Note: market share is based on volume Source Symphony Health Source: IQVIA Investor Relations 2022 9

View entire presentation